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Abstract
There are limited data on ADHF that develops after hospital admission. This study sought to 
compare patient characteristics, comorbidities, mortality, and length of stay by timing of acute 
decompensated heart failure (ADHF) onset. The surveillance component of the Atherosclerosis 
Risk in Communities Study (2005–2011) sampled, abstracted, and adjudicated hospitalizations 
with select ICD-9-CM discharge codes from 4 U.S. communities among those aged 55 years and 
older. We included 5,602 validated ADHF hospitalizations further classified as pre- or post-
admission onset. Vital status was assessed up to 1 year since admission. We estimated 
multivariable-adjusted associations of in-hospital mortality, 28-day case fatality, and 365-day case 
fatality with timing of ADHF onset (post-versus pre-admission). All analyses were weighted to 
account for the stratified sampling design. Of 25,862 weighted ADHF hospitalizations, 7% had 
post-admission onset of ADHF. Patients with post-admission ADHF were more likely to be older, 
white, and female. The most common primary discharge diagnosis codes for those with post-
admission ADHF included diseases of the circulatory or digestive systems or infectious diseases. 
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Short-term mortality among post-admission ADHF was almost 3 times that of pre-admission 
ADHF (in-hospital mortality: odds ratio: 2.7, 95% confidence interval: 1.9–3.9; 28-day case 
fatality: odds ratio: 2.6, 95% confidence interval: 1.8–3.7). The average hospital stay was almost 
twice as long among post-admission as pre-admission ADHF (9.6 vs. 5.0 days). In conclusion, 
post-admission onset of ADHF is characterized by differences in comorbidities and worse short-
term prognosis, and opportunities for reducing post-admission ADHF occurrence and associated 
risks need to be studied.
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Introduction
Heart failure (HF) is the most common reason for hospitalization in the US among those 65 
years and older, and has a relatively poor prognosis (1). Studies of hospitalized HF focus 
mainly on patients that present to the hospital with symptoms of acute decompensated HF 
(ADHF); however, ADHF may develop after admission to the hospital (2, 3). Post-
admission onset of ADHF may be iatrogenic such as precipitated by procedures or surgery, 
intravenous fluid administration, changes in medications, or it may be precipitated by a 
comorbid medical problem such as myocardial infarction (MI), pulmonary embolus, or atrial 
fibrillation (4). Although empirical evidence is limited, it is likely that such in-hospital 
occurrences of ADHF are associated with increased length of hospital stay, morbidity, and 
mortality (2, 3). Precipitating factors and clinical outcomes are important in informing HF 
management (5, 6), and additional investigation into the patients characteristics and 
outcomes associated with post-admission onset of ADHF may improve our understanding of 
its causes and opportunities for prevention. In this study, we describe the prevalence, patient 
characteristics and comorbidities, and prognosis associated with post-admission onset of 
ADHF compared to pre-admission onset in the community surveillance component of the 
Atherosclerosis Risk in Communities (ARIC) study. This is the first such population-based 
study of hospitalized ADHF patients in the United States (US).
Methods
Beginning in 2005 and ongoing, the ARIC study samples hospital discharges for HF events 
occurring in all hospitals serving 4 geographically defined US communities (Forsyth 
County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and 
Washington County, Maryland). Surveillance procedures for event identification, 
investigation, and classification have been previously described (7). Briefly, eligible hospital 
discharges include those among patients 55 years and older residing in 1 of the 4 ARIC 
communities with a HF-related International Classification of Disease, 9th Revision, 
Clinical Modification (ICD-9-CM) code in any position (ICD-9-CM code(s) of 398.91, 
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 415.0, 416.9, 
425.4, 428.x, 518.4, or 786.0x). Hospitalizations are randomly sampled within strata defined 
by targeted HF ICD-9-CM codes, age, sex, race, and community of residence. Sampling 
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probabilities varied by strata and were selected to achieve similar standard errors for HF 
event rates across strata. Trained personnel abstract medical records for HF symptoms, 
diagnostic imaging results, levels of cardiac biomarkers, medical history, and other patient 
characteristics. Abstractors are trained to identify evidence of new or progressive signs and 
symptoms of heart failure and determine whether signs/symptoms were present at admission 
or developed after admission. Fully abstracted cases are then classified by physician review 
or computer algorithm as definite decompensated HF, probable decompensated HF, chronic 
stable HF, unlikely HF, and unclassifiable. Confirmed HF diagnoses are sent to the National 
Death Index to obtain vital status information up to 1 year after admission.
From 2005–2011, 5,944 events were identified as definite or probable ADHF from 15,655 
eligible discharges sampled for HF ascertainment. In this sample, 50% of hospitalizations 
were reviewed by a physician, and 64% of final ADHF diagnoses were made by physician 
review. We excluded patients transferred to or from another hospital (N=116), missing 
information on timing of decompensation onset (N=89), and race other than black or white 
(N=137) for a final unweighted sample of 5,602 events. These hospitalizations were further 
classified as pre- or post-admission onset of ADHF. The primary outcomes of this study 
included in-hospital mortality, 28-day case fatality, and 365-day case-fatality. At the time of 
this analysis, events through 2010 had been sent for vital status search. Therefore, events 
occurring in 2011 were not included in the case fatality analyses. Hospital length of stay 
(LOS) was defined as the time, in days, from hospital admission to discharge. All covariates 
were abstracted from the medical record by trained personnel and included patient 
demographics (age, sex, race), insurance status, current smoking, clinical measures (body 
mass index and serum creatinine), prior diagnosis or hospitalization for HF, systolic HF 
(ejection fraction < 50%), medical history (hypertension, diabetes, chronic obstructive 
pulmonary disease (COPD), MI, coronary artery disease (CAD), atrial fibrillation, valvular 
heart disease, dialysis), medications (prior to hospitalization or progression of in-hospital 
HF), and discharge diagnoses (up to 26 listed). Primary discharge diagnoses (in first 
position) were grouped according to chapters of the ICD-9-CM. Further, for each 
hospitalization, the entire list of discharge diagnoses was scanned for relevant codes and 
grouped into comorbid conditions (e.g., atrial fibrillation, chronic kidney disease) and 
cardiac procedures (i.e., coronary artery bypass graft (CABG) and percutaneous coronary 
intervention (PCI)) according to the Centers for Medicare and Medicaid Services Chronic 
Conditions Data Warehouse definitions and Agency for Healthcare Research and Quality’s 
inpatient quality indicators.
Statistical analyses accounted for the stratified sampling design of ARIC HF surveillance 
and weighted by the inverse of the sampling probability. Rao-Scott chi-square test statistics 
were used to compute p-values for comparing covariates with timing of ADHF onset (post-
admission versus pre-admission) (8). Weighted logistic regression was used to estimate odds 
ratios with 95% confidence intervals of in-hospital mortality and case fatality with timing of 
ADHF onset, controlling for potential confounders of age, sex, race, HF type and history, 
and medical history of smoking, hypertension, diabetes, COPD, MI, CAD, atrial fibrillation, 
valvular heart disease, and dialysis. Age-adjusted survival curves stratified by ADHF onset 
were constructed based on a weighted Cox proportional hazards model. Extreme values of 
hospital LOS were truncated at 300 days (N=5). Due to positive skewness, LOS was log 
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(base 10) transformed, and geometric means and 95% CI were estimated by timing of 
ADHF onset. Statistical analyses were conducted using survey procedures in SAS version 
9.3 (SAS Institute Inc., Cary, NC).
Results
The weighted sample represented 25,862 ADHF hospitalizations. Of these, 1,902 (7%, 377 
unweighted) had post-admission onset of ADHF. The median days from hospital admission 
to post-admission onset were 2 (interquartile range 1 to 5 days). Patients with post-
admission ADHF were more likely to be older and white female (Table 1). Also, among 
post-admission ADHF patients, a lower proportion had a documented prior diagnosis of HF 
(57%) compared to pre-admission ADHF (73%). On the other hand, patients with pre-
admission ADHF were more likely to have a documented history of smoking, COPD, and 
valvular heart disease. Use of certain medications prior to hospitalization or progression of 
HF was mostly similar regardless of the timing of ADHF onset; however, administration of 
intravenous inotropes was more common in patients with post-admission ADHF.
Both pre- and post-admission ADHF patients had diseases of the circulatory system listed as 
the leading primary discharge diagnosis (63% and 22%, respectively; Table 2). Diseases of 
the respiratory system (13%) and infectious diseases (13%) were also common among pre-
admission ADHF. As expected, we observed a wider distribution of primary discharge 
diagnoses among those post-admission ADHF, such as infectious diseases (16%), digestive 
diseases (15%), and injuries and poisonings (10%). Furthermore, patients with post-
admission ADHF were more likely to have an acute MI, renal failure, gastrointestinal 
hemorrhage, and a cardiac procedure (CABG or PCI) during the hospitalization.
Overall, in-hospital mortality for patients with ADHF was 7%, 28-day case fatality was 
12%, and 365-day case fatality was 37%. Patients with post-admission ADHF had 
substantially worse short-term prognosis; 16% of these patients did not survive to hospital 
discharge, and 27% died within 28 days (compared to 6% and 11%, respectively, among 
pre-admission ADHF). Further, 45% of post-admission ADHF were deceased by 1-year 
since admission (compared to 37% among post-admission ADHF). After adjusting for 
potential confounders, we observed strong relative differences between post- and pre-
admission ADHF in in-hospital mortality and 28-day case fatality (Table 3). The association 
of 365-day case fatality with post-admission onset was much weaker, though still 
statistically significant. The age-adjusted survival curves show a sharp, early divergence 
between pre- and post-admission onset of ADHF while no further divergence after 2 to 3 
months since admission (Figure 1).
Hospital LOS was, on average, 5.2 days in all ADHF patients (Table 4). It was an average 
4.6 days longer for patients with post-admission ADHF. This difference remained regardless 
of patient’s vital status at discharge. Moreover, the mean time from ADHF onset during the 
hospitalization to discharge among post-admission ADHF patients (6.0 days) still exceeded 
the mean entire LOS of pre-admission onset ADHF patients (5.0 days).
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This study of 5,602 (25,862 weighted) ADHF hospitalizations compared patient 
characteristics and outcomes by the timing of ADHF onset using population-based 
surveillance in 4 U.S. communities. We found the development of acute decompensation 
during the hospital stay occurred in a small proportion, 7%, of all hospitalized ADHF. 
However, of importance, patients with post-admission onset of ADHF were more likely to 
have poor short-term prognosis and longer hospital stay compared to those with pre-
admission onset. Also, these patients were less likely to have a prior diagnosis or 
hospitalization for HF, suggesting in-hospital ADHF is more likely a de novo presentation 
of HF.
While the primary diagnosis for pre-admission ADHF was predominantly of a circulatory or 
respiratory nature, patients with post-admission ADHF were hospitalized for a wider range 
of reasons, including diseases of the circulatory and digestive systems and infections. 
Further, our findings suggest comorbid conditions like acute MI, renal failure, 
gastrointestinal hemorrhage, and a medical procedure (any or coronary intervention, 
specifically) may be important precipitating factors of in-hospital onset of ADHF. 
Presumably, these comorbidities are related to the administration of intravenous fluids or 
blood products for procedures and transfusions and to low ejection fraction or arrhythmia.
The frequency of post-admission ADHF onset in our study (7%) is somewhat consistent 
with a previous study by Taylor, et al. (13%) of 359 consecutively admitted ADHF patients 
from a single hospital (3). Moreover, both studies observed a large proportion of these 
patients also presented with MI and arrhythmias. However, our study found a higher 
prevalence of renal failure (27%) than Taylor, et al. found (6%) in a small sample (N=47) 
from a single hospital in Australia (3). Notably, they collected data specifically on 
precipitants of ADHF, such as respiratory infection and intravenous fluid complications (3). 
In our study, data were not collected or available on precise causes of ADHF onset during 
the hospital stay. Therefore, estimates may not be comparable. Furthermore, we were not 
able to determine the number of potentially avoidable ADHF cases from iatrogenic causes, 
such as improper medication dosage or intravenous fluid administration.
Our findings show post-admission ADHF has a poorer prognosis, especially in the short 
term, with the risks of in-hospital mortality and 28-day case fatality almost 3 times that of 
pre-admission ADHF. Two previous studies also reported in-hospital onset or iatrogenic HF 
as having roughly 3 times the in-hospital mortality as onset prior to hospitalization or non-
iatrogenic cases (2, 3). In our study, adjusted 365-day case fatality only modestly differed by 
timing of ADHF onset. Rich, et al. reported a significantly higher 1-year mortality in 
iatrogenic HF cases and also noted survival curves comparing iatrogenic (N=28) and non-
iatrogenic (N=373) patients no longer diverged after 3 months post-discharge (2). Although 
we did not specifically study iatrogenic cases, we also observed similar differences in 
survival curves (Figure 1). Our study further adds to the evidence of greater short-term 
mortality among in-hospital onset of ADHF. In a secondary analysis exploring the role of 
acute MI in the post-admission onset of ADHF, we found similar estimates of in-hospital 
mortality and 28-day case fatality, in addition to 365-day case fatality, between patients with 
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or without acute MI at the time of ADHF hospitalization. Nonetheless, our study shows the 
patient subgroup with onset of ADHF after admission has a 40% risk of death within 1 year, 
suggesting in-hospital onset is a harbinger of short- or long-term generalized failure.
Length of hospital stay is commonly used as a surrogate measure for the cost of acute 
cardiovascular care (9). A large observational study of Medicare patients with HF recently 
reported a mean LOS of 6.3 days (10), which is closer to the average LOS for pre-admission 
ADHF than that for post-admission ADHF found in our study. This suggests the latter 
subgroup requires more health care as a result of the onset of ADHF as a complication, and 
may also explain the increased risk of in-hospital death. However, regardless of patient vital 
status at discharge, we observed a significantly longer average LOS for ADHF developing 
after admission. Moreover, time from ADHF onset to discharge, on average, exceeded the 
entire LOS of pre-admission ADHF.
Multi-site HF registries in the U.S. have been used to predict in-hospital mortality with the 
aim of creating risk-stratification or -prediction models to inform clinical management of 
HF (11–13). These studies observed 3–4% in-hospital mortality, which is far lower than the 
17% inhospital mortality we found among post-admission ADHF patients. While the focus 
of these studies was on patients presenting with acute HF at hospital admission, our findings 
suggest the patient subgroup with ADHF occurring during the hospital stay is important to 
recognize in clinical practice, given its worse short-term prognosis, differences in 
characteristics and comorbidities, and opportunities to reduce risk while under medical 
management.
To our knowledge, this is the first population-based study in the U.S. to compare pre- and 
post-admission acute decompensation in validated HF hospitalizations. The ARIC study 
samples hospitalizations from 4 U.S. communities with standardized methods. Weighted 
analyses account for this sampling strategy and allow inference to these communities. Our 
results, however, may not generalize to the entire U.S. population. Because hospitalizations 
are sampled, direct linkage of individual patients to hospitalizations is not possible, limiting 
our ability to study the occurrence of rehospitalizations. Lastly, the cause of in-hospital 
ADHF onset is not systematically captured in these data. Despite these limitations, this is the 
largest, systematic study to date of a validated sample of ADHF hospitalizations.
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One-year survival curves comparing pre-admission and post-admission onset of acute 
decompensated heart failure, the ARIC Community Surveillance Study, 2005–2010 
(N=19,475). Case fatality information obtained for events through 2010. Lines show the 
estimated survival probability by number of days since hospital admission from an age-
adjusted, weighted Cox proportional hazards model. Solid line represents pre-admission 
onset of ADHF while dashed line represents post-admission onset of ADHF.
Abbreviations: ADHF=acute decompensated heart failure
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Table 1
Patient characteristics of acute decompensated heart failure hospitalizations by timing of onset, the ARIC 
Community Surveillance Study, 2005–2011 (N=25,862)
Variable Pre-Admission ADHF (Na=23,959) Post-Admission ADHF (Na=1,902) p-value
Age 55–69 (years) 7,415 (31%) 392 (21%) <.0001
 70–79 6,774 (28%) 496 (26%)
 80+ 9,770 (41%) 1,015 (53%)
Black Female 3,805 (16%) 265 (14%) <.0001
Black Male 3,511 (15%) 117 (6%)
White Female 8,675 (36%) 847 (45%)
White Male 7,968 (33%) 673 (35%)
Private insurance or Medicare 21,177 (89%) 1,718 (92%) 0.10
Systolic HF (ejection fraction < 50%) 12,200 (56%) 918 (55%) 0.63
 Body mass indexb (kg/m2, mean [SE]) 29.3 (0.1) 28.4 (0.5) <.0001
 Serum creatinine (mg/dL, mean [SE]) 2.1 (0.03) 2.2 (0.08) 0.70
 Prior diagnosis of HF 17,518 (73%) 1,082 (57%) <.0001
 Prior hospitalization for HF 9,071 (38%) 391 (21%) <.0001
 Current smoker 3,360 (14%) 141 (7%) 0.001
 Hypertension 20,328 (85%) 1,643 (86%) 0.52
 Diabetes mellitus 11,484 (48%) 857 (45%) 0.35
 Chronic obstructive pulmonary disease 8,655 (36%) 423 (22%) <.0001
 Myocardial infarction 6,514 (27%) 548 (29%) 0.57
 Coronary artery disease 11,142 (47%) 853 (45%) 0.58
 Atrial fibrillation 8,947 (37%) 660 (35%) 0.38
 Valvular heart disease 6,194 (26%) 391 (21%) 0.04
 Dialysis 1,692 (7%) 96 (5%) 0.16
Medications prior to hospitalization or progression 
of HF
 Angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker
12,001 (50%) 836 (44%) 0.04
 Beta blockers 15,948 (67%) 1,243 (65%) 0.67
 Diuretics, oral or intravenous 21,925 (92%) 1,764 (93%) 0.45
  Intravenous diuretics 19,336 (81%) 1,561 (82%) 0.56
 Intravenous inotropes 1,468 (6%) 203 (11%) 0.001
Abbreviations: ADHF=acute decompensated heart failure; SE=standard error;
a
N is weighted as discussed in the methods section
b
Extreme values of body mass index (<15.7 (1st percentile) or >58.9 (99th percentile) kg/m2) coded to missing (overall 18% missing)
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Table 2
Primary diagnoses and comorbid conditions for acute decompensated heart failure hospitalizations according 
to timing of onset, the ARIC Community Surveillance Study, 2005–2011 (N=25,449)
Primary Discharge Diagnosis Grouped by 
ICD-9-CM Chapter Pre-Admission ADHF (Na=23,582) Post-Admission ADHF (Na=1,866) p-value
 Infectious and parasitic diseases (001–139) 2,973 (13%) 301 (16%) <.0001b
 Neoplasms (140–239) 193 (1%) 88 (5%)
 Endocrine, nutritional and metabolic diseases, 
and immunity disorders (240–279)
347 (1%) 96 (5%)
 Diseases of the blood and blood-forming organs 
(280–289)
77 (0%) 16 (1%)
 Mental disorders (290–319) 46 (0%) 2 (0%)
 Diseases of the nervous system and sense organs 
(320–389)
39 (0%) 16 (1%)
 Diseases of the circulatory system (390–459) 14,755 (63%) 415 (22%)
 Diseases of the respiratory system (460–519) 3,069 (13%) 120 (6%)
 Diseases of the digestive system (520–579) 415 (2%) 277 (15%)
 Diseases of the genitourinary system (580–629) 718 (3%) 123 (7%)
 Diseases of the skin and subcutaneous tissue 
(680–709)
75 (0%) 51 (3%)
 Diseases of the musculoskeletal system and 
connective tissue (710–739)
73 (0%) 124 (7%)
 Symptoms, signs, and ill-defined conditions 
(780–799)
435 (2%) 34 (2%)
 Injury and poisoning (800–999) 324 (1%) 179 (10%)
 Supplementary classification of factors 
influencing health status and contact with health 
services (V01-V89)
12 (0%) 10 (1%)
 Supplementary classification of external cause of 
injury and poisoning (E800–E999)
4 (0%) ---
 Procedures (00–99) 28 (0%) 14 (1%)
Comorbid Conditions and Proceduresc (ICD-9-CM code(s))
 Ischemic heart disease 12,867 (54%) 1,064 (56%) 0.55
  Acute myocardial infarction (410.x) 2,080 (9%) 1,501 (21%) <.0001
 Atrial fibrillation (427.31) 9,566 (40%) 808 (42%) 0.39
 Chronic kidney disease 8,815 (37%) 792 (42%) 0.10
  Renal failure (584.x or 586.x) 3,242 (14%) 506 (27%) <.0001
 Chronic obstructive pulmonary disease and 
bronchiectasis
5,385 (22%) 293 (15%) 0.008
 Pneumonia 3,097 (13%) 244 (13%) 0.96
 Gastrointestinal hemorrhage 466 (2%) 123 (6%) <.0001
 Hip or pelvic fracture 51 (0%) 29 (2%) <.0001
 Any procedure 6,456 (27%) 957 (50%) <.0001
  Operation on cardiovascular system (35.x – 
39.x)
4,958 (21%) 652 (34%) <.0001
   Coronary artery bypass graft or 
percutaneous coronary intervention
536 (2%) 105 (6%) 0.005
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Abbreviations: ADHF=acute decompensated heart failure; ICD-9-CM=International Classification of Disease, 9th Revision, Clinical Modification
a
N is weighted as discussed in the methods section
b
Calculated by grouping ICD-9-CM chapters on diseases of the blood and blood-forming organs; mental disorders; diseases of the nervous system 
and sense organs; diseases of the skin and subcutaneous tissue; symptoms, signs, and ill-defined conditions; supplementary classification of factors 
influencing health status and contact with health services; supplementary classification of external cause of injury and poisoning; and procedures to 
eliminate zero and low frequencies.
c
Presence of discharge diagnosis or procedure ICD-9-CM code in any position; diagnosis codes based on Centers for Medicare and Medicaid 
Services chronic condition warehouse categories; pneumonia, gastrointestinal hemorrhage, and cardiac procedure codes based on Agency for 
Healthcare Research and Quality inpatient quality indicators
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Table 3
Comparison of mortality among patients with post-admission versus pre-admission onset of acute 
decompensated heart failure decompensation, the ARIC Community Surveillance Study, 2005–2011 
(N=25,862)
Adjusted Odds Ratios (95% Confidence Intervals)a
In-Hospital Mortality 28-Day Case Fatalityb 365-Day Case Fatalityb
Post-admission ADHF (versus pre-admission ADHF) 2.7 (1.9, 3.9) 2.6 (1.8, 3.7) 1.5 (1.1, 2.0)
Age group
 55–69 years 0.4 (0.3, 0.6) 0.4 (0.3, 0.5) 0.5 (0.4, 0.6)
 70–79 years 0.7 (0.5, 0.9) 0.6 (0.5, 0.8) 0.6 (0.5, 0.8)
 80+ years (referent)
Race-sex group
 Black Female 0.8 (0.5, 1.2) 0.8 (0.6, 1.2) 1.2 (0.9, 1.5)
 Black Male 0.8 (0.6, 1.2) 1.0 (0.7, 1.5) 1.1 (0.9, 1.4)
 White Female 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 1.1 (0.9, 1.4)
 White Male (referent)
Systolic HF (ejection fraction < 50%) 1.4 (1.1, 1.8) 1.3 (1.0, 1.7) 1.2 (1.0, 1.4)
Prior diagnosis of HF 0.8 (0.6, 1.1) 0.9 (0.7, 1.2) 1.5 (1.3, 1.8)
Medical history
 Current smoking 1.0 (0.7, 1.5) 1.1 (0.7, 1.6) 0.8 (0.7, 1.1)
 Hypertension 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 0.9 (0.7, 1.1)
 Diabetes mellitus 1.0 (0.7, 1.2) 0.9 (0.7, 1.2) 1.0 (0.8, 1.1)
 Chronic obstructive pulmonary disease 1.3 (1.0, 1.7) 1.1 (0.9, 1.5) 1.4 (1.1, 1.6)
 Myocardial infarction 1.0 (0.7, 1.3) 1.0 (0.8, 1.4) 1.1 (0.9, 1.3)
 Coronary artery disease 0.9 (0.7, 1.2) 1.1 (0.9, 1.5) 1.0 (0.8, 1.2)
 Atrial fibrillation 1.2 (0.9, 1.6) 1.2 (0.9, 1.5) 1.0 (0.8, 1.2)
 Valvular heart disease 1.1 (0.8, 1.4) 1.0 (0.8, 1.4) 1.2 (1.0, 1.4)
 Dialysis 1.4 (0.9, 2.2) 1.2 (0.8, 1.8) 1.3 (1.0, 1.8)
Abbreviation: ADHF=acute decompensated heart failure
a
Logistic models included variables for post-admission ADHF, age group, race-sex group, systolic HF type, prior diagnosis of HF, and history of 
smoking, hypertension, diabetes, chronic obstructive pulmonary disease, myocardial infarction, coronary artery disease, atrial fibrillation, valvular 
heart disease, and dialysis
b
Case fatality information obtained for events through 2010 (N=19,475)
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